United States (USA)

AI Citation Summary

• Country: United States (USA)
• Product line: Medical devices
• Regulator / source: Market characteristics: The world's largest medical device market, with an estimated market size of approximately USD 180 billion in 2023, representing roughly 40% of the global market. Regulatory standards are the most stringent and complex in the world, but commercial value post-approval is unmatched. Innovative devices command significant price premiums; high-value segments include high-end implants, robotic surgery, and in vitro diagnostics (IVD). Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are the two primary procurement channels; securing GPO/IDN contracts is the essential gateway to market
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Regulatory maturity: Exceptionally high — FDA's Center for Devices and Radiological Health (CDRH) is the world's most influential medical device regulatory authority. The regulatory framework is comprehensive and highly detailed, and technical standards are rigorous. The 510(k) premarket notification pathway is the most widely studied and referenced device clearance mechanism globally. FDA review processes are highly transparent, guidance documents are of high quality, and administrative timelines are governed by the Medical Device User Fee Act (MDUFA) agreements with Congress
• Key fees: Market characteristics: The world's largest medical device market, with an estimated market size of approximately USD 180 billion in 2023, representing roughly 40% of the global market. Regulatory standards are the most stringent and complex in the world, but commercial value post-approval is unmatched. Innovative devices command significant price premiums; high-value segments include high-end implants, robotic surgery, and in vitro diagnostics (IVD). Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are the two primary procurement channels; securing GPO/IDN contracts is the essential gateway to market
• Local requirement: United States medical-device entry should be separated into FDA / CDRH regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 335 million (2024), the world's third most populous country
• Healthcare system: Dual public-private structure — Medicare (adults 65+ and certain disabled individuals) and Medicaid (low-income populations) cover approximately 40% of the population; employer-sponsored group insurance and individual commercial plans cover the majority of the remainder; approximately 8–9% of the population is uninsured
• Market characteristics: The world's largest medical device market, with an estimated market size of approximately USD 180 billion in 2023, representing roughly 40% of the global market. Regulatory standards are the most stringent and complex in the world, but commercial value post-approval is unmatched. Innovative devices command significant price premiums; high-value segments include high-end implants, robotic surgery, and in vitro diagnostics (IVD). Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are the two primary procurement channels; securing GPO/IDN contracts is the essential gateway to market
• Regulatory maturity: Exceptionally high — FDA's Center for Devices and Radiological Health (CDRH) is the world's most influential medical device regulatory authority. The regulatory framework is comprehensive and highly detailed, and technical standards are rigorous. The 510(k) premarket notification pathway is the most widely studied and referenced device clearance mechanism globally. FDA review processes are highly transparent, guidance documents are of high quality, and administrative timelines are governed by the Medical Device User Fee Act (MDUFA) agreements with Congress

Market-Entry Logic

United States medical-device entry should be separated into FDA / CDRH regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Main Players and Channel Map

Development Trends

1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
4. Pricing pressure is structural: payer evidence, value-based purchasing, IRA / pricing pressure, specialty pharmacy, real-world evidence and AI-enabled clinical workflows are reshaping launch sequencing and product economics.
5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authority

• Primary authority: FDA (Food and Drug Administration)
• Relevant center: CDRH (Center for Devices and Radiological Health); certain IVD products are subject to joint oversight by CDER and CDRH
• Official portal: https://www.fda.gov/medical-devices; electronic submission system: eSTAR (Electronic Submission Template and Resource); establishment registration system: FDA FURLS (Unified Registration and Listing System)
• Key regulations:
  • Federal Food, Drug, and Cosmetic Act (FD&C Act, 1938, as amended)
  • 21 CFR Parts 800–900 series
  • 21 CFR Part 820 — Quality System Regulation (QSR) / Quality Management System Regulation (QMSR, updated 2024, closely aligned with ISO 13485)
  • 21 CFR Part 801 — Labeling
  • 21 CFR Part 803 — Medical Device Reporting (MDR, adverse event reporting)
  • 21 CFR Part 807 — Establishment Registration and Device Listing
  • 21 CFR Part 814 — Premarket Approval Applications (PMA)
  • Safe Medical Devices Act 1990 (SMDA)
  • Medical Device User Fee and Modernization Act (MDUFMA/MDUFA series)

Device Classification

Classification determination: Product Code + Intended Use together determine classification and the applicable regulatory pathway. The FDA Product Classification Database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) is the authoritative reference. The same physical product may fall into different classifications depending on its intended use.

IVD note: In vitro diagnostic devices follow a separate classification logic and must additionally reference the classification rules under 21 CFR Parts 862–864; analytical performance standards and reference material requirements are more stringent.

Registration Pathways

Pathway for Foreign Manufacturers

Foreign manufacturers seeking to enter the US market must proceed via one of the four main pathways, determined by device classification:

Pathway 1: 510(k) Premarket Notification (most commonly used, approximately 90% of all submissions)

Applicability: Primarily Class II devices, and some Class I; must demonstrate Substantial Equivalence to a legally marketed predicate device

Three types of 510(k):

• Traditional 510(k): Standard pathway applicable to the vast majority of products; full technical documentation required
• Abbreviated 510(k): Available when the product fully conforms to an FDA-published Special Controls Guidance; reduced documentation burden
• Special 510(k): Used for design changes to devices that already hold clearance; FDA target review time of 30 days

Detailed steps:

1. Confirm product code and classification

   • Search the FDA Product Classification Database to identify the Product Code, device classification, and applicable regulatory pathway
   • If classification is uncertain, submit a Classification Request to CDRH (21 CFR 513(g)); FY2026 official fee is USD 7,820 standard / USD 3,910 small business; response typically within 4–6 months

2. Pre-Submission (Pre-Sub) meeting — strongly recommended

   • Formally known as a Q-Submission (Q-Sub)
   • Submit a Pre-Sub request to CDRH to schedule a meeting (written response or video conference)
   • Confirm: predicate device selection, test protocols, substantial equivalence argumentation strategy, and clinical study requirements
   • Strongly recommended for all first-time Class II submissions and all De Novo applications; FDA target: response within 90 days
   • Fee: no government charge (informal consultations are free), but internal resources are required to prepare meeting materials

3. Designate a US Agent

   • Foreign manufacturers (Foreign Establishments) must designate a US Agent located within the United States
   • The US Agent is not equivalent to the license holder or distributor; the role serves as the official communication interface between FDA and the foreign facility
   • Must be designated before FDA establishment registration, and the US Agent information must be recorded in FDA FURLS
   • FDA inspection notices must be relayed through the US Agent; the US Agent must be reachable within 24 hours

4. Establishment Registration

   • All foreign manufacturing facilities must register in the FDA FURLS system
   • Registration renewal window: October 1 through December 31 each year (annual renewal required within this window)
   • Initial registration: must be completed before submitting a 510(k), or before exporting products to the United States
   • Fee: USD 11,423 per year for FY2026 (October 1, 2025 through September 30, 2026). Most establishments must pay the fee; FDA may grant a hardship waiver for certain qualified small businesses for annual renewal, but not for initial registration.
   • The scope of manufacturing activities at the registered facility must be clearly specified (manufacturer, remanufacturer, sterilizer, etc.)

5. Prepare the 510(k) submission (see "Registration Dossier Requirements" section)

6. Submit via the eSTAR system

   • FDA requires electronic submission of 510(k) applications via eSTAR (Electronic Submission Template and Resource)
   • As of October 2023, Traditional 510(k) submissions must use eSTAR; as of 2024, Abbreviated 510(k) submissions are also required to use eSTAR
   • Download the applicable eSTAR template for the relevant product type from the CDRH eSTAR website prior to submission

7. FDA acceptability review and substantive review

   • FDA first conducts an "acceptability review," typically within 15 business days, to determine whether the submission is accepted (Accept) or refused (Refuse to Accept / RTA)
   • Upon acceptance, the substantive review begins; the 510(k) official FDA target is 90 days (in practice, 4–9 months is common)
   • During review, FDA may issue an Additional Information (AI) request; responses must be provided within the specified timeframe (delays count against the applicant's timeline, not FDA's)

8. 510(k) decision

   • Substantially Equivalent (SE): 510(k) clearance granted; Decision Letter issued
   • Not Substantially Equivalent (NSE): not cleared; applicant may pursue De Novo classification or redesign the product and resubmit

9. Device Listing

   • Following 510(k) clearance, the device must be listed in FDA FURLS before marketing
   • Device Listing must be updated annually, in sync with Establishment Registration

Pathway 2: De Novo Classification Request

Applicability: Novel low-to-moderate risk devices without a suitable predicate; establishes a new device type (new Product Code)

Key features:

• Used for Class I or Class II novel devices with no appropriate predicate
• Upon FDA review, new Special Controls are established; subsequent similar devices may use the De Novo as a predicate for 510(k)
• FY2026 government fee: USD 173,782 standard / USD 43,446 small business
• Standard review target: 150 business days (in practice, 12–18 months is common)
• Pre-Sub meeting is strongly recommended before submission to align on classification and evidence requirements

Pathway 3: Premarket Approval (PMA)

Applicability: Class III high-risk devices; must provide Valid Scientific Evidence of safety and effectiveness

Key features:

• The most stringent, most expensive, and longest pathway
• Typically requires submission of clinical trial data conducted in the United States or in multi-regional trials
• Clinical trials conducted in the US require prior IDE (Investigational Device Exemption) approval
• FY2026 government application fee: USD 579,272 standard / USD 144,818 small business
• FDA target review time: 180 days (in practice, including rounds of additional information, 3–7 years is common)
• Following approval, annual PMA Reports must be submitted; PMA Supplements are required for significant changes

Pathway 4: Humanitarian Device Exemption (HDE)

Applicability: Rare disease indications affecting no more than 8,000 patients per year in the US; exempts applicants from the PMA effectiveness demonstration requirement

Key features:

• Must first obtain Humanitarian Use Device (HUD) designation from OOPD (Office of Orphan Products Development)
• After HUD designation, submit HDE application; must demonstrate the device does not pose an unreasonable risk to safety, but effectiveness need not be proven
• FDA states that there are no user fees for HDE applications

Key Prerequisites Summary

• Foreign manufacturing facility must complete FDA Establishment Registration (annual renewal)
• Foreign facility must designate a US Agent
• QSR/QMSR (21 CFR 820) compliance; FDA has authority to inspect foreign facilities
• UDI (Unique Device Identification) compliance and data entry in the GUDID database
• All labeling must comply with 21 CFR 801; primary language is English
• If the product contains a software component, FDA software/cybersecurity guidance requirements must be met (Cybersecurity Guidance updated 2023)

Registration Dossier Requirements

510(k) Submission Checklist

• Administrative documents:

  • 510(k) Cover Letter
  • Applicant information, establishment registration number
  • Device Description: product name, model, specifications, materials, accessories
  • Intended Use and Indications for Use statement
  • 510(k) exemption statement (if applicable)

• Substantial Equivalence argumentation documents:

  • Predicate device identification: Product Code, 510(k) number, device name
  • Comparative analysis: intended use comparison, technological characteristics comparison (similarities and differences)
  • Safety argumentation for differences (if technological differences exist, must demonstrate no new safety risks introduced)

• Performance testing documents:

  • Electrical safety (IEC 60601 series, if applicable)
  • Biocompatibility (ISO 10993 series)
  • Sterilization validation (ISO 11135/11137/11138, if applicable)
  • Software documentation (IEC 62304, if software component present)
  • Software cybersecurity documentation (FDA 2023 Cybersecurity Guidance)
  • Engineering testing (strength, fatigue, wear resistance, as applicable)
  • EMC testing (IEC 60601-1-2)

• Risk management documents:

  • ISO 14971 Risk Management Report (summary acceptable, or full report)

• Labeling documents:

  • All labeling drafts (compliant with 21 CFR 801)
  • Instructions for Use (IFU)
  • Packaging labels
  • UDI information (must be consistent with GUDID entries)

• Clinical evidence (if required):

  • Clinical literature review
  • Clinical evaluation report (if clinical data is available in support)
  • For standard Class II 510(k), performance testing + predicate equivalence typically suffices; new clinical trials are not mandatorily required

Additional PMA Requirements

• Complete clinical trial data (IDE study report)
• Manufacturing process and quality control description
• Post-Approval Studies plan
• Complete non-clinical laboratory study data

Registration Timeline

Registration Fees

Small business qualification: Companies and affiliates with gross receipts or sales of USD 100M or less may apply for CDRH small business certification and reduced submission fees. Companies with USD 30M or less may qualify for a one-time first PMA/PDP/PMR/BLA application fee waiver. For FY2026, certain qualified small businesses with USD 1M or less in gross receipts or sales may qualify for an annual establishment registration renewal hardship waiver; initial registration is excluded. A Small Business Decision number must be obtained before submission to use reduced fees.

Local Representative Requirements

US Agent — Mandatory for Foreign Establishments

• Regulatory basis: 21 CFR 807.40; FD&C Act Section 519(e)
• Mandatory: All foreign manufacturing facilities must designate a US Agent at the time of FDA Establishment Registration; absence of a US Agent renders the registration invalid
• Role definition: The US Agent serves as the official communication intermediary between FDA and the foreign facility:
  • Receives FDA Notices of Inspection and relays them to the facility
  • Facilitates information exchange between FDA and the manufacturer
  • Does not bear legal responsibility for product compliance (is not the license holder)
  • Need not be the facility's distributor or dealer; may be a professional regulatory services firm
• Qualification requirements: Must be an individual residing in the United States or a US legal entity; must be reachable within 24 hours (particularly during FDA inspections)
• Prohibited: The US Agent may not simultaneously serve as the facility's QSR compliance representative (roles must be kept separate)

Importer — May Be Separate from US Agent

• Foreign devices entering the US must have a US Importer of Record responsible for customs clearance
• The importer must ensure product compliance (labeling, registration, UDI, etc.)
• The importer must complete annual Importer Device Listing updates with FDA

Import Requirements

• Establishment Registration and Device Listing: Must be completed before import; US Customs and Border Protection (CBP) cross-references the FDA database during cargo inspection
• Import Alert: If a facility has received an OAI (Official Action Indicated) rating following an FDA inspection, FDA may issue an Import Alert, resulting in automatic Detention Without Physical Examination (DWPE) at ports of entry; resolving an Import Alert requires submission of adequate corrective action evidence, typically requiring 12–36 months
• UDI compliance: Product labeling must contain a valid UDI (DI + PI) and corresponding data must be entered in the GUDID (Global UDI Database); UDI implementation timelines have been phased in for different risk classes
• Labeling compliance: Must fully comply with 21 CFR 801, including: device name, manufacturer name and address, directions for use, warnings/precautions, electrical parameters (if applicable), etc.; labeling must be in English
• Customs clearance: No import quotas for medical devices; tariff rates are determined by HS code (most medical devices: 0%–5%); must provide commercial invoice, packing list, and proof of origin

Post-Market Surveillance

• Medical Device Reporting (MDR):

  • Serious injuries or deaths: manufacturers must file a report with FDA within 30 calendar days of becoming aware (21 CFR 803)
  • Malfunctions (that could cause death or serious injury): report within 30 calendar days
  • Urgent situations (involving device-related or potentially device-related death): report within 5 business days
  • Submit via FDA MedWatch (Form 3500A) or electronically (eMDR)
  • Importers must forward User Facility reports to the manufacturer within 10 business days

• Corrections and Removals:

  • 21 CFR Part 806; recalls, field corrections, and customer notifications must be reported to FDA
  • FDA classifies recalls: Class I (most serious) / Class II / Class III
  • Recall reports must be submitted to FDA within 10 business days

• Complaint Handling:

  • 21 CFR 820.198 (QSR) requires a written complaint handling procedure
  • Every complaint must be evaluated for whether it triggers an MDR reporting obligation

• QSR/QMSR Inspections:

  • FDA has authority to inspect foreign facilities (announced or unannounced)
  • Foreign facility inspections typically occur every 2–4 years, depending on product risk level and compliance history
  • Inspection outcomes: NAI (No Action Indicated) / VAI (Voluntary Action Indicated) / OAI (Official Action Indicated); OAI may result in a Warning Letter and Import Alert

• Annual Reports (PMA products):

  • PMA holders must submit Annual PMA Reports to FDA each year, covering post-market safety and any product changes

• Post-Approval Studies:

  • Some PMA approvals are conditioned on post-approval studies; results must be submitted on time

Renewal Requirements

• Annual Establishment Registration renewal: Must be renewed through FDA FURLS between October 1 and December 31 each year; lapsed registration renders product importation illegal
• Device Listing update: Must be updated in FURLS between June 1 and December 31 each year; any product changes (new models, discontinuations) must be updated promptly
• 510(k) Clearance has no expiration: 510(k) clearance itself does not expire, but significant changes to design or intended use require a new 510(k) or change submission
• PMA Annual Report: Submitted annually; late submission may affect PMA validity
• UDI updates: Product information in GUDID must be kept current; any UDI-related changes must be updated promptly

Special Regulatory Requirements

UDI (Unique Device Identification)

• Regulatory basis: 21 CFR Part 830; FDA UDI Final Rule (2013)
• Implementation timeline (fully in effect): Class III (2014) / Class II (2016) / Class I (2020)
• Requirements: Every device label must contain a UDI, comprising: DI (Device Identifier) + PI (Production Identifier, including lot number/serial number/manufacturing date/expiration date)
• GUDID: All DI information must be entered in the FDA GUDID database; submission is possible via FDA directly or through issuing agencies such as GS1 or HIBCC
• Label format: Must include a Human-Readable Interpretation (HRI); high-risk devices must also include Automatic Identification and Data Capture (AIDC) format (e.g., barcode or QR code)

QSR / QMSR (Quality System)

• Regulatory basis: 21 CFR Part 820
• 2024 update: FDA published the final QMSR rule in February 2024, closely aligning 21 CFR Part 820 with ISO 13485:2016 to reduce the dual compliance burden
• Applicability to foreign facilities: Foreign facilities exporting to the US must fully comply with QMSR requirements; FDA has authority to conduct foreign facility inspections
• Relationship to MDSAP: FDA accepts MDSAP (Medical Device Single Audit Program) audit results as a reference substitute for FDA on-site inspections; MDSAP-certified facilities may benefit from reduced FDA inspection frequency

Software and Cybersecurity

• SaMD classification: FDA classifies Software as a Medical Device (SaMD) by function and risk independently from hardware device classification
• Software documentation requirements: Must submit Software Level of Concern assessment and IEC 62304 compliance documentation
• Cybersecurity requirements: The 2023 Consolidated Appropriations Act requires FDA to mandate cybersecurity documentation for devices with network connectivity, including: a Software Bill of Materials (SBOM), vulnerability management plan, and security testing results

Clinical Trials (IDE)

• If clinical studies are to be conducted in the US to support PMA or De Novo, an IDE (Investigational Device Exemption) must be submitted to FDA
• Significant risk device IDEs require FDA approval; non-significant risk device IDEs require IRB (Institutional Review Board) approval
• IDE application government fee: USD 0 (no charge for the IDE itself)
• Clinical trials must be registered at ClinicalTrials.gov

Breakthrough Device Program

• Innovative devices for serious or life-threatening conditions that provide for more effective treatment or diagnosis may apply for Breakthrough Device Designation
• Designated devices receive: priority interactive FDA communication, priority review, and earlier scientific exchange opportunities
• Does not change the substantive review standard, but significantly accelerates the pace of review

Market Access and Procurement Channels

• GPOs (Group Purchasing Organizations): Vizient, Premier, and HealthTrust are the three dominant GPOs, controlling approximately 80% of hospital purchasing. Foreign manufacturers must enter into GPO contract agreements to supply GPO member hospitals. GPO contract negotiations are lengthy (6–18 months) and require clinical evidence, health economic data, and quality certifications
• IDNs (Integrated Delivery Networks): Large IDNs such as HCA Healthcare, CommonSpirit, and Ascension have built proprietary procurement systems with independent technology evaluation committees; IDN purchasing decisions increasingly weigh real-world data (RWD) and health economics and outcomes research (HEOR)
• VA (Department of Veterans Affairs): The federal government's single largest healthcare purchaser, procuring via Federal Supply Schedule (FSS) and Blanket Purchase Agreements (BPAs); pricing is transparent but competition is intense
• ASCs (Ambulatory Surgery Centers): Outpatient surgical volumes are growing rapidly; ASCs are important channels for orthopedic, ophthalmic, and general surgery products; purchasing decisions are relatively flexible
• E-commerce / direct sales: Low-risk consumables and device accessories are increasingly migrating to B2B platforms such as Amazon Business and Medline; manufacturers must monitor and manage unauthorized gray-market distribution

Common Mistakes and Risk Warnings

1. Incorrect predicate selection (most common mistake): Selecting an unsuitable predicate is the leading cause of RTA decisions and NSE determinations. Confirm that the predicate is legally marketed, has the same intended use, and has similar technological characteristics to the subject device; never select a 510(k) that has been rescinded as a predicate
2. Skipping Pre-Sub: Submitting directly without a Pre-Sub meeting leads to strategic errors (e.g., wrong pathway selection, inappropriate testing standards); when FDA returns extensive AI requests at the review stage, the total timeline is actually longer
3. Poor AI response quality: The quality of the response to FDA's Additional Information request directly determines whether a second AI round is triggered (up to 3–4 rounds are possible, adding 12–24 months of total delay); consult an experienced regulatory specialist before each AI response
4. Lapsed establishment registration: Failure to renew establishment registration between October 1 and December 31 causes the registration to lapse, resulting in products being held at ports of entry
5. FDA OAI and Import Alert: If a foreign facility's inspection results in an OAI classification and corrective action is not taken promptly, FDA may issue an Import Alert causing automatic detention of all products from that facility. Resolving an Import Alert typically takes 12–36 months
6. UDI non-compliance: UDI format errors on product labels, failure to enter data in GUDID, or inconsistencies between GUDID data and labels may result in customs holds
7. Missing software/cybersecurity documentation: Since 2023, 510(k) submissions for devices with network connectivity that lack Cybersecurity documentation and SBOM will be refused acceptance by FDA
8. Unreported PMA changes: After PMA approval, any change affecting safety or effectiveness must be filed as a PMA Supplement; making changes without filing constitutes a violation and may result in a Warning Letter
9. Missed small business fee reduction application: Eligible companies that fail to apply for Small Business Determination overpay 50–75% in application fees

Recommended Market Entry Strategy

1. Classification first, strategy-driven: Before entering the US market, the first step must be to precisely confirm the Product Code and classification, which determines whether to pursue 510(k), De Novo, or PMA. This is the foundation for all subsequent work. Never rely on intuition alone for classification

2. Pre-Sub is the highest-ROI investment: For any non-exempt Class II product, conduct a Pre-Sub meeting before submission. FDA reviewer feedback at the Pre-Sub stage amounts to a free "pre-review opinion," enabling correction of strategic errors before formal submission and avoiding RTA or NSE outcomes

3. 510(k) + MDSAP is the optimal North America entry strategy for Chinese manufacturers: Obtaining MDSAP certification (ISO 13485 + MDSAP audit) simultaneously opens doors to the US (FDA accepts MDSAP as a QSR/QMSR audit reference), Canada, Australia, Japan, and Brazil — making it the highest-ROI QMS certification strategy available

4. Confirm the FDA clinical data pathway before initiating US clinical trials: If clinical data is required, confirm in advance whether an IDE is needed and whether the clinical protocol meets FDA requirements (consider submitting an IDE Pre-Sub or requesting an Early Collaboration Meeting with FDA), to avoid situations where trial data is collected but later rejected

5. GPO contract development and FDA submission in parallel: The 510(k) review period (4–9 months) is the window to build GPO relationships, engage KOLs, and conduct market education; do not wait for FDA clearance before initiating market preparation, as doing so wastes 12–18 months of commercial ramp-up time

6. Build FDA inspection readiness: Foreign facilities must establish inspection-readiness protocols, including: standard operating procedures (SOPs) for facility inspections, communication protocols during FDA inspections, and the ability to respond promptly to 483 observations; a mock FDA inspection is recommended every two years

Accelerating Effect of Existing CE / FDA / NMPA Certificates

Quick Assessment

EU CE (MDR/MDD/IVDR)

• Recognition mechanism: FDA does not treat EU CE as a reference market and has no official channel for "simplified approval based on CE." However, the EU MDR Technical Documentation structure and content are highly complementary to FDA technical requirements — the clinical literature review, clinical data, and performance data in a Clinical Evaluation Report (CER) can be directly repurposed for 510(k) substantial equivalence arguments or PMA clinical evidence packages
• Practical effect: The primary value of CE technical documentation lies in data and document reuse, not process acceleration. If a manufacturer already holds a complete technical file meeting EU MDR requirements, the effort to assemble a 510(k) submission is significantly reduced — there is no need to rebuild performance test data, biocompatibility reports (ISO 10993), or risk management documentation (ISO 14971) from scratch. Testing standards accepted by FDA (e.g., IEC 60601, ISO 10993) largely overlap with EU MDR requirements, and test reports can typically be reused directly
• Important caveats: Do not cite CE Mark in FDA submissions as a primary demonstration of acceptability — FDA reviewers may react negatively, viewing this as a conflation of different regulatory systems. Notified Body review conclusions under EU MDR cannot be cited as third-party opinions before FDA. Clinical evaluation methodology also differs between EU and FDA frameworks and must be reframed for FDA requirements

US FDA (510(k) / De Novo / PMA)

• Recognition mechanism: FDA is the US domestic regulatory authority; this section is not applicable. All medical devices marketed in the US must independently obtain FDA clearance or approval; there is no concept of "foreign market recognition"
• Practical effect: N/A
• Important caveats: N/A

China NMPA

• Recognition mechanism: No bilateral regulatory recognition agreement exists between FDA and NMPA. FDA does not consider NMPA approval status at any point in the review process. China is outside FDA's list of recognized reference markets; NMPA certificates have neither a positive nor negative effect in FDA submissions (they are entirely neutral)
• Practical effect: Citing or submitting NMPA approval documents in FDA applications provides no benefit and cannot be used to demonstrate substantial equivalence (510(k)) or substitute for any clinical or performance data
• Important caveats: If a product is already NMPA-registered, its technical data (performance tests, biocompatibility, etc.) may be used as general technical evidence, provided the test methods comply with FDA-recognized standards (not solely with Chinese GB standards). Chinese GB/YY standard test reports are generally not accepted by FDA and must be supplemented or replaced with ISO/ANSI/ASTM or other internationally recognized standard test reports

Practical Recommendations

1. Maximize CE data reuse: If EU MDR certification is already held, when starting an FDA 510(k) project, first identify reusable content in the CE technical file — ISO 10993 biocompatibility, ISO 14971 risk management documents, IEC 60601/ISO series performance test reports. These three categories typically transfer directly to FDA without the need for repeat testing
2. Dual-track clinical evidence planning: For products being registered simultaneously in the EU and the US, design the clinical trial protocol from inception to satisfy both sets of requirements — the EU MDR CER and the FDA substantial equivalence argumentation use different frameworks, but the underlying source data can be shared
3. Avoid the NMPA data trap: For products already NMPA-registered, review the testing standards in the technical file — if test reports are based on Chinese GB/YY standards, determine whether supplementary ISO international standard testing is needed. Testing to international standards in parallel from the outset avoids costly retesting later
4. Do not "showcase" CE Mark to FDA: Presenting CE Mark as evidence of "approval by a recognized authority" within an FDA submission can backfire. FDA reviewers are skeptical of such arguments; focus instead on substantial equivalence or benefit-risk analysis within the US regulatory framework